BackBiogen Overview

Biogen Intangible Assets

Biogen's intangible assets is $9.1B.

Get informed when a big investor buys or sells

+ Follow
Intangible Assets
$9.05B
↓ 5.54% YoYΔ $-531.10M vs prior year quarter

Peer average

Loading

Biogen Intangible Assets History

Loading

Biogen vs. peers: Intangible Assets Comparison

Loading

Biogen Intangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Biogen (BIIB) FAQ

As of the most recent data (March 2026), BIIB shows a intangible assets of $9.1B. That compares with $9.6B in the prior-year period — down 5.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BIIB's intangible assets is now $9.1B (was $9.6B) — a 5.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Biogen is outperforming or lagging.

Tracking BIIB's intangible assets over time shows whether Biogen is scaling, shrinking, or reshaping that part of the business. The current reading is $9.1B That compares with $9.6B in the prior-year period — down 5.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this intangible assets page, Stockcircle has Biogen's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect intangible assets (currently $9.1B) with ownership activity and broader fundamentals.

Biogen's intangible assets is $9.1B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.